NRAS and cancer: Directly targeting the RAS oncoprotein itself may exploit the high degree of oncogene addiction of KRASG12X (and NRAS)-mutated cancer cells to a greater degree than targeting upstream and downstream signalling proteins (such as SHP2, MEK1/2 and ERK1/2).